Jeil Pharma Holdings제일파마홀딩스

Jeil Pharma Holdings shows a thin recovery in trailing profit after losses in 2022 to 2024, while its share price has fallen over the past year.

Jeil Pharma Holdings is a Korean holding company whose subsidiaries make and sell prescription and over-the-counter medicines. Trailing twelve-month revenue to H1 2026 was ₩631B with an operating margin of 2.9% and a net margin of 1.3%, so profitability remains thin. The shares closed at ₩7,040 on 2026-10-26, down 15.8% over one year and about 29% below the 52-week high of ₩9,850.

What stands out

• 2025 was the strongest year in the data, with revenue of ₩658B, operating income of ₩38.7B and net income of ₩14.6B, after operating and net losses in 2021, 2022 and 2024.
• Revenue has fallen in 2025 (down 15.7%) and the trailing figures show revenue of ₩631B, so top-line momentum is weak.
• Balance sheet: cash of ₩62.7B against borrowings of ₩21.9B, with liabilities at 89.5% of equity; trailing free cash flow was negative at about -₩0.9B.
• Valuation metrics are low (P/E 13.3, P/B 0.4, dividend yield 1%), but the data gives a DCF base value of ₩2,378 and a bear value of ₩0, which sit far below the share price, and peers trade at different multiples.
• Recent filings include a corporate value-up plan (2026-10-22), the H1 2026 half-year report with an amendment, and several insider and 5%+ holding reports; no news headlines were provided.

What to watch

• The next quarterly or half-year results and whether operating margin holds above the trailing 2.9%.
• The detail of the corporate value-up plan filed on 2026-10-22, including any dividend or shareholder return commitments, which the data does not describe.
• Whether free cash flow turns positive and whether revenue decline continues, given the weak trailing trend.